Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: racke mk. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Mycophenolate mofetil in multiple sclerosis.
Frohman EM, Brannon K, Racke MK, Hawker K. Frohman EM, et al. Among authors: racke mk. Clin Neuropharmacol. 2004 Mar-Apr;27(2):80-3. doi: 10.1097/00002826-200403000-00006. Clin Neuropharmacol. 2004. PMID: 15252268
Multiple sclerosis--the plaque and its pathogenesis.
Frohman EM, Racke MK, Raine CS. Frohman EM, et al. Among authors: racke mk. N Engl J Med. 2006 Mar 2;354(9):942-55. doi: 10.1056/NEJMra052130. N Engl J Med. 2006. PMID: 16510748 Review. No abstract available.
Pharmacological treatment of early multiple sclerosis.
Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Stüve O, et al. Among authors: racke mk. Drugs. 2008;68(1):73-83. doi: 10.2165/00003495-200868010-00005. Drugs. 2008. PMID: 18081373 Review.
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. del Pilar Martin M, et al. Among authors: racke mk. Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13. Arch Neurol. 2008. PMID: 18852339 Clinical Trial.
Translational research in neurology and neuroscience 2010: multiple sclerosis.
Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN. Stüve O, et al. Among authors: racke mk. Arch Neurol. 2010 Nov;67(11):1307-15. doi: 10.1001/archneurol.2010.158. Epub 2010 Jul 12. Arch Neurol. 2010. PMID: 20625066 Free PMC article. Review.
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Frohman EM, et al. Among authors: racke mk. Neurology. 2003 Sep 9;61(5):602-11. doi: 10.1212/01.wnl.0000082654.99838.ef. Neurology. 2003. PMID: 12963748
199 results